Market revenue in 2020 | USD 50.1 million |
Market revenue in 2028 | USD 101.2 million |
Growth rate | 9.2% (CAGR from 2020 to 2028) |
Largest segment | Cancer |
Fastest growing segment | Hematology Diseases |
Historical data covered | 2016 - 2019 |
Base year for estimation | 2020 |
Forecast period covered | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease |
Key market players worldwide | Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.
Cancer was the largest segment with a revenue share of 14.37% in 2020. Horizon Databook has segmented the Latin America rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.
Lack of information and deficient legal and regulatory leads to lack of coverage in the Latin American health systems. This has resulted in availability of proper diagnosis and treatment of rare disease in the region.
In order to address this, a considerable number of research studies are being conducted in the region to address the technical and scientific concerns in this area. These factors are expected to spur investment in the development of diagnostics for rare diseases across the Latin American countries.
In addition, presence of health agencies such as La Federación Argentina de Enfermedades Poco Frecuentes (Argentina Federation of Rare Diseases) introducing technological advances in scientific research pertaining to rare disease is expected to boost revenue share of this region in the coming years.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America rare disease genetic testing market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account